Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3Active not recruiting 3Recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Specimen Handling 125pembrolizumab 123Magnetic Resonance Spectroscopy 108Carboplatin 89Cyclophosphamide 80Biopsy 69Cisplatin 67Paclitaxel 61Bevacizumab 56Gemcitabine 54Nivolumab 49fludarabine 48Dexamethasone 41Rituximab 39Pemetrexed 39Fluorouracil 39Radiotherapy 37Doxorubicin 37atezolizumab 36Docetaxel 36Leucovorin 35Oxaliplatin 32Capecitabine 32venetoclax 31Temozolomide 29Prednisone 29durvalumab 27Standard of Care 27Radiation 27Letrozole 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × nilotinib × 30 days × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT04449549 2026-05-22

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
82 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡